| Subject: | FDA Informs Healthcare Professionals of Ongoing Data Review of Vytorin, Zetia and Zocor |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 28 Jan 2008 - 10:00 am |
| Audience: Cardiovascular healthcare professionals and patientsThe FDA is informing healthcare professionals about an ongoing data review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor). This early communication is in keeping with FDA's commitment to inform the public about ongoing post-marketing drug issues.Merck/Schering Plough Pharmaceuticals reported preliminary results from the Effect of Combination Ezetimibe and... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|